Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“The biparatopic anti-HER2 mAb Anbenitamab, combined with neoadjuvant taxane, improved pCR rate vs THP for HER2+ eBC.
Anbetimab, similar to zanidatamab, targets the same HER2 epitopes of H+P: this trial first may show that combining their targeting in a single mAb is more active.”
Other articles about Breast Cancer on OncoDaily.